T-Triomax solution 25 mg / ml 4 ml ampoule № 10

T-Triomax (T-TRIOMAX) instructions for use

Composition

active substance: morpholinium salt of thiazotonic acid; 1 ml morpholinium salt of thiazotonic acid 25 mg
excipients: water for injection.

Dosage form

Injection.

Basic physical and chemical properties:

transparent colorless or slightly yellowish liquid.

Pharmacological group

Cardiological preparations. ATX C01E C code

Pharmacological properties

Pharmacodynamics.

The active substance of the drug has anti-ischemic, membrane-stabilizing, antioxidant and immunomodulating action.

The mechanism of action of the drug is associated with increased compensatory activation of anaerobic glycolysis and activation of oxidation processes in the Krebs cycle, while maintaining the intracellular ATP.

The presence in the structure of the molecule of the morpholinium salt of the thiazotonic acid of the thiol of sulfur, for which the redox properties are characteristic, and the tertiary nitrogen, which binds the excess of hydrogen ions, activates the antioxidant system. The strong reducing properties of the thiol group cause a reaction with the active forms of oxygen and lipid radicals, and the reactivation of antiradical enzymes - superoxide dismutase, catalase and glutathione peroxidase - prevents the initiation of reactive oxygen species.

Improvement of rheological properties of blood is carried out due to the activation of the fibrinolytic system.

The effect leads to inhibition of lipid oxidation in ischemic areas of the myocardium, a decrease in the sensitivity of the myocardium to catecholamines, prevention of progressive suppression of the contractile function of the heart, stabilization and reduction, respectively, of the necrosis zone and myocardial ischemia.

Improving the metabolic processes of the myocardium, increasing its contractility, promoting the normalization of the heart rate allows us to recommend a drug for treating patients with various forms of coronary heart disease.

In parallel with the use of the drug in cardiology, it is used in the treatment of diseases of the liver and other internal organs, given its high hepatoprotective properties. Morpholinium salt of thiazotonic acid prevents the destruction of hepatocytes, reduces the degree of fatty infiltration and the spread of centrolobular liver necrosis, promotes the processes of reparative regeneration of hepatocytes, normalizes protein, carbohydrate, lipid and pigment metabolism in them. It also increases the rate of synthesis and excretion of bile, normalizes its chemical composition.

Pharmacokinetics.

When administered, the maximum concentration of morpholinium salt of thiazotonic acid in blood plasma is reached after 0.84 hours, with intravenous salt after 0.1 hours. Binding with blood proteins is not more than 10%. Accumulated mainly in the kidneys - 31%, as well as in large quantities in the large intestine, heart, spleen, least of all - in the small intestine and lungs (1-2%).

Indications

In the complex treatment of coronary heart disease: angina pectoris, myocardial infarction, postinfarction cardiosclerosis.

As an additional tool in the therapy of cardiac arrhythmias.

In the complex treatment of chronic hepatitis, alcoholic hepatitis, fibrosis and cirrhosis of the liver.

Contraindications

Hypersensitivity to the active ingredient or other components of the drug.

Interaction with other drugs and other interactions

As a cardio-and hepatoprotective drug can be used in combination with basic means of therapy of coronary heart disease and combine with traditional methods of treatment of hepatitis of the corresponding etiology.

Application features

Use during pregnancy and lactation

There is insufficient experience in the use of the drug during pregnancy and lactation.

The ability to influence the reaction rate when driving vehicles or other mechanisms

In case of adverse reactions from the central and peripheral nervous system, care must be taken when driving vehicles and working with other mechanisms.

Dosing and Administration

For myocardial infarction and unstable angina pectoris, administer the drug slowly at 4 ml 25 mg / ml (100 mg) at a rate of 2 ml / min or intravenously drip at a rate of 20-30 drops per minute (4 ml of a solution of 25 mg / ml diluted in 150 -250 ml 0.9% solution of sodium chloride) or administered intramuscularly 4 ml 25 mg / ml (100 mg) 2-3 times a day. The course of treatment is 14 days.

With stenocardia of tension and rest and postinfarction cardiosclerosis, the drug should be administered intramuscularly 2 ml 25 mg / ml 3 times a day. The course of treatment is 20-30 days.

For chronic hepatitis with a pronounced activity of the preparation, intramuscularly 2 ml 25 mg / ml (50 mg) 2-3 times a day or intravenously slowly at a rate of 2 ml / min per 4 ml 25 mg / ml in the first 5 days (100 mg) once a day, or drip at a rate of 20-30 drops per minute (2 ampules 25 mg / ml solution diluted in 150-250 ml of 0.9% sodium chloride solution).From the 5th to the 20th day of therapy, use the drug in the form of tablets (100 mg 3 times per day).

For chronic hepatitis of a minimal and moderate degree of activity, the drug should be administered intramuscularly 2 ml 25 mg / ml 3 times a day. The course of treatment is 20-30 days.

With liver cirrhosis, the treatment should begin with intramuscular injection of 2 ml 25 mg / ml (50 mg) 3 times a day for 5 days, and then continue with the treatment with tablets (100 mg 3 times daily). The course of treatment is 60 days.

Children

There is insufficient experience in using the drug in children.

Overdose

Symptoms: increased concentration of sodium and potassium in the urine.

Treatment: withdrawal of the drug, symptomatic therapy.

Adverse Reactions

The drug is usually well tolerated.

In patients with increased individual sensitivity may occur:

From the skin and subcutaneous tissue: itching, skin flushing, rash, hives,

from the side of the immune system: against the background of taking other medications, cases of angioedema, anaphylactic shock;

others: fever, chills and changes in the injection site.

In patients, mainly the elderly, when taking other drugs, there may be:

from the central and peripheral nervous system: general weakness, dizziness, tinnitus, headache

from the cardiovascular system: tachycardia, arterial hypertension, cases of lowering blood pressure;

from the digestive tract: manifestations of dyspeptic phenomena, including dry mouth, nausea, bloating, vomiting

from the respiratory system: shortness of breath, suffocation.

Shelf life

2 years.

Storage conditions

Store in the original packaging at a temperature not higher than 25 ° C. Do not freeze. Keep out of the reach of children.

Packaging

2 ml or 4 ml in the ampoule; 5 ampoules in a planar cell package; 2 contour packs per pack.

Category of leave

On prescription.